Identification of relapse-specific NT5C2 mutations, previously reported in acute lymphoblastic leukemia35 but never in APL or non-APL AMLs, genetically demonstrates that cytarabine and/or 6-Mercaptopurine have therapeutic efficacy in APL28,51. Here, NT5C2 is linked to acute promyelocytic leukemia.